Smart algorithm aims to tailor blood thinner use after stents

NCT ID NCT05732701

Recruiting now Disease control Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a risk-score algorithm can safely personalize how long patients take dual antiplatelet therapy (two blood thinners) after getting a heart stent. About 2,788 participants will be assigned to either algorithm-guided or standard treatment duration. The goal is to reduce both bleeding and clotting complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor such as clopidogrel or ticagrelor)
What this could lead to: If successful, this could provide a safer, personalized approach to blood thinner use after heart stent procedures, reducing both bleeding and clotting risks.
What could go wrong: This is a large but early-stage algorithm-based study; the score may not outperform standard care, and individual patient factors could still lead to unexpected bleeding or clotting events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE PERCUTANEOUS CORONARY INTERVENTION PLATELET AGGREGATION INHIBITORS

Contacts and locations

Locations

Department of Cardiology, Bern University Hospital
RECRUITING

Bern, 3010, Switzerland
UOC Cardiologia San Giovanni Addolorata Hospital
RECRUITING

Roma, 00184, Italy
University Clinical Center of the Republic of Srpska
RECRUITING

Banja Luka, 78000, Bosnia and Herzegovina

More trials for these conditions

Other studies related to the condition(s) this trial covers.